Heart Failure/Transplantation
Secondary analysis of a RCT | Effects of Empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure.
26 Aug, 2022 | 13:24h | UTCCommentary: Empagliflozin Offers Clinical Benefit in Heart Failure – HealthDay
Original Study: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine
Observational study suggests Hydroxychloroquine is associated with increased risk of cardiovascular events compared to Methotrexate in patients with heart failure.
25 Aug, 2022 | 11:56h | UTCCardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Editorial: Hydroxychloroquine: Heart-Throb No More? – Journal of the American College of Cardiology
Commentary: Caution needed with hydroxychloroquine use in older RA patients with heart failure – medwire News
Left ventricular assist devices: a primer for the non-mechanical circulatory support provider.
17 Aug, 2022 | 13:51h | UTC
RCT | Sustained-release ivabradine hemisulfate in patients with systolic heart failure.
16 Aug, 2022 | 13:01h | UTC
RCT | Omecamtiv Mecarbil does not improve exercise capacity in chronic heart failure with reduced ejection fraction.
15 Aug, 2022 | 12:07h | UTCEffect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Author Interview: Can Omecamtiv Mecarbil Improve Peak Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)? – JAMA
Commentaries:
Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF – Medscape (free registration required)
Commentary on Twitter
#OriginalInvestigation: Multicenter randomized clinical trial found that, in patients with chronic #HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. @GLewisCardiol https://t.co/f27Y0oya6S
— JAMA (@JAMA_current) July 20, 2022
Cohort Study | Age at menopause and risk of heart failure and atrial fibrillation.
5 Aug, 2022 | 14:38h | UTCAge at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study – European Heart Journal (link to abstract – $ for full-text)
Editorial: Premature menopause and cardiovascular disease: can we blame estrogen? – European Heart Journal
News Release: Premature menopause is associated with increased risk of heart problems – European Society of Cardiology
RCT | Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction.
3 Aug, 2022 | 14:06h | UTC
Commentary on Twitter
No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… ? https://t.co/79gSEwon4y
— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022
Review | Management of heart failure in patients with chronic kidney disease.
1 Aug, 2022 | 11:59h | UTCManagement of Heart Failure in Patients with Chronic Kidney Disease – European Cardiology Review
M-A | Mortality and clinical predictors after percutaneous mitral valve repair for secondary mitral regurgitation.
26 Jul, 2022 | 11:49h | UTC
Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study.
22 Jul, 2022 | 11:18h | UTC
Commentary from the author on Twitter
In an international collaborative analysis, we developed a decision-support tool (CoDE-HF) that rules-in and rules-out acute heart failure more accurately than any approach using NT-proBNP thresholds alone- published today @bmj_latest https://t.co/JtPBEzcGqu pic.twitter.com/bCo9Xlzt5b
— Ken Lee (@KuanKenLee) June 13, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license
Review | Temporary mechanical circulatory support: devices, outcomes, and future directions.
14 Jul, 2022 | 12:23h | UTC
RCT | Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.
13 Jul, 2022 | 11:52h | UTC
AHA Science Advisory | Elucidating the clinical implications and pathophysiology of pulmonary hypertension in heart failure with preserved ejection fraction: a call to action.
13 Jul, 2022 | 11:40h | UTC
M-A | Oral iron supplementation in patients with heart failure.
13 Jul, 2022 | 11:17h | UTC
AHA Scientific Statement | Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock.
8 Jul, 2022 | 12:05h | UTCTop Things to Know: Escalating and De-escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock– American Heart Association
Commentary: Guiding Cardiogenic Shock Management: Filling in the (Wide) Data Gaps – American Heart Association
Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.
8 Jul, 2022 | 11:53h | UTCRelated:
AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.
Case Series | Myocardial injury in patients with acute and subacute Chagas Disease in the Brazilian Amazon using cardiovascular magnetic resonance.
5 Jul, 2022 | 11:47h | UTCTrends in advanced heart failure therapy: update on cardiac transplantation.
4 Jul, 2022 | 12:07h | UTCCohort Study: B‐Type Natriuretic Peptide and long‐term cardiovascular mortality in patients with coronary heart disease.
1 Jul, 2022 | 11:04h | UTC
RCT: Effects of early Empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure.
30 Jun, 2022 | 11:24h | UTC
Secondary analysis of a RCT: Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes.
30 Jun, 2022 | 10:58h | UTCOriginal Study: Empagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine
M-A: Comparison of mortality and hospital readmissions among patients receiving virtual ward transitional care vs. usual postdischarge care.
29 Jun, 2022 | 12:06h | UTC
Commentary on Twitter
In this systematic review and meta-analysis of 24 RCTs, post-discharge virtual ward care was associated with reduced all-cause mortality, hospital readmission, and healthcare costs in patients with heart failure. https://t.co/yMx7F52L5S
— JAMA Network Open (@JAMANetworkOpen) June 28, 2022
Retrospective Cohort Study: Atrial fibrillation after surgery is linked to an increased risk of hospitalization for heart failure.
29 Jun, 2022 | 10:52h | UTCOriginal Study: Post-operative atrial fibrillation and risk of heart failure hospitalization – European Heart Journal
Commentary on Twitter
Excited to have been part of this study with @ParagGoyalMD and our @WeillCornell colleagues
We found post-operative AF is associated with a higher long-term risk of HF hospitalization ?https://t.co/X9eh2D9V71 @ESC_Journals @WCMCNeurology pic.twitter.com/5HlsGfOq1j
— Hooman Kamel (@hoomankamel) June 29, 2022
Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.
29 Jun, 2022 | 10:50h | UTC
Review: Arrhythmias and heart failure in pregnancy.
29 Jun, 2022 | 10:48h | UTC